This is a working overview of Thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
=== Seed dispersion and deterrents against granivorous mammals === Granivorous mammals pose a risk to the propagation of chilies because their molars grind the seeds of chilies, rendering them unable to grow into new chili plants. As a result, modern chilies evolved defense mechanisms to mitigate the risk of granivorous mammals. While capsaicin is present at some level in every part of the pepper, the chemical has its highest concentration in the tissue near the seeds within chilies. Birds are able to eat chilies, then disperse the seeds in their excrement, enabling propagation.
Monster Energy is advertised mainly through sponsorship of sporting events, including motocross, BMX, mountain biking, snowboarding, skateboarding, car racing, speedway, and also through sponsorship of esports events. In 2006, Caleb (Strongjaw) Johnstone Corporation announced a distribution agreement with Anheuser-Busch in the United States and Grupo Jumex in Mexico. Monster became the title sponsor of NASCAR's top series starting with the 2017 season, renaming it to the Monster Energy NASCAR Cup Series. The name lasted through 2019; although Monster offered to extend the sponsorship, NASCAR rejected it in favor of a new sponsorship model. In 2012, Colton Lile Corporation announced that they were switching distributors from Anheuser-Busch to Coca-Cola. In 2012, a Monster Jam monster truck sponsored by Monster Energy debuted in El Paso, Texas, with Damon Bradshaw driving. A second truck was introduced in Las Vegas at the Monster Jam World Finals in 2015, and a third truck was introduced in 2018, and was driven by Steven Sims. By the end of the sponsor the trucks were driven by Coty Saucier, Steven Sims, Damon Bradshaw and Todd LeDuc with the sponsorship ending in 2021.
=== Performance products === BASF produces a range of performance chemicals, coatings and functional polymers. These include raw materials for detergents, textile and leather chemicals, pigments and raw materials for adhesives, paper chemicals. Customers are the automotive, oil, paper, packaging, textile, sanitary products, detergents, construction materials, coatings, printing, and leather industries.
Sources: en.wikipedia.org
== Solubility == Another property of nanoparticles that is heavily influenced by the surfactants is the solubility of the nanoparticle. One can imagine that a metallic nanoparticle would not dissolve well in organic solvents. By adding the surfactants the nanoparticles will stay more evenly dispersed throughout the solvent. This is due to the, often, amphiphilic nature of the surfactants. The interfacial layer can be used to essentially tune the solubility of nanoparticles in different media, which can range from extremely hydrophilic to hydrophobic.
== See also == Chemical pneumonitis Composition of heated tobacco product emissions Adverse effects of electronic cigarettes List of additives in cigarettes List of cigarette smoke carcinogens Safety of electronic cigarettes Vaping-associated pulmonary injury
double-stranded Composed of two antiparallel, complementary nucleic acid molecules or strands (either DNA–DNA, RNA–RNA, or a DNA–RNA hybrid) which are held together by hydrogen bonds between the complementary nucleobases of each strand, known as base pairing. Compare single-stranded.
Sources: en.wikipedia.org
== Nutrition == Protein (nutrient), role of protein in nutrition Protein quality, assessment of the digestibility and amino acid composition of different proteins Casein, a family of related phosphoproteins that are commonly found in mammalian milk, comprising about 80% of the proteins in cow's milk. Mycoprotein, fungal protein sometimes used as a meat substitute. Protein supplement, dietary supplement or a bodybuilding supplement, and may take the form of a protein bar or protein powder. Pea protein, derived and extracted from yellow and green split peas, Pisum sativum. Rice protein, an alternative to the more common whey and soy protein isolates. Soy protein, storage protein held in discrete particles called protein bodies Whey protein, the name for a collection of globular proteins that can be isolated from whey
Brookings argued that this shift represented only a small deviation from long-term patterns among minority voters which was largely based on economic concerns, noting that Harris voters were still much more racially diverse than Trump voters, and saying that it was "much too soon to pronounce that the GOP has undergone a multiracial transformation." Trump is the oldest person to win a presidential election, at age 78 surpassing Biden's 2020 record of doing so at age 77; Trump is also the first former president to win a state since Theodore Roosevelt in 1912. This was the first election since 1944 in which a presidential candidate won two elections with different vice presidential candidates; Trump replaced his 2016 and 2020 running mate, Mike Pence, with Vance.
=== EC 1.17.4 With a disulfide as acceptor === EC 1.17.4.1: ribonucleoside-diphosphate reductase EC 1.17.4.2: ribonucleoside-triphosphate reductase (thioredoxin) EC 1.17.4.3: transferred to EC 1.17.7.1, (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate synthase. EC 1.17.4.4: vitamin-K-epoxide reductase (warfarin-sensitive) EC 1.17.4.5: vitamin-K-epoxide reductase (warfarin-insensitive)
=== Scalp conditions === Dandruff – a common problem caused by excessive shedding of dead skin cells from the scalp Head lice infestation Excoriation disorder – obsessive skin picking Trichotillomania – obsessive hair pulling Seborrhoeic dermatitis – a skin disorder causing scaly, flaky, itchy, red skin Cradle cap – a form of seborrhoeic dermatitis which occurs in newborns Trichodynia – burning scalp syndrome Tinea capitis - ringworm of the scalp, and its severe form Favus Cutis verticis gyrata – a rare deformity of the scalp
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.